Hikma Pharmaceuticals, a multinational pharmaceutical company, announced on Wednesday that it has received preliminary approval from the US Federal Trade Commission (FTC).
The company will now work to complete its previously announced acquisition of Custopharm from Water Street Healthcare Partners on September 27, 2021.
- Advertisement -
The parties have now received all necessary regulatory approvals to complete the deal. Hikma will make another announcement after the transaction is completed.
Hikma Pharmaceuticals shares dropped 1.4% to 2,052p despite the company receiving approval from the FTC.